The NGS market is growing, and LaserGen provides a very attractive investment opportunity in this environment.
Over the past few years, NGS technologies have replaced the traditional Sanger method and have substantially increased the overall market size for DNA sequencing. The leading factor driving growth in this market is large-scale whole genome and targeted genome re-sequencing of humans. Other factors shaping the market include growth in the study of large-scale genetic variation within populations, and discovery of causative mutations in rare and common diseases and cancer. The market for NGS is fast moving, increasing, and important.
Please contact us if you would like to discuss investment or partnership opportunities with LaserGen.
The statements in this news release regarding the benefits, potential utility, commercial value and functionality of the diagnostic kit to be developed by LaserGen are forward-looking statements that involve risks and uncertainties. These risks include the risk that the product may not receive regulatory clearance for marketing, that potential customers will not readily adopt the new product, that it will not provide the anticipated benefits due to technical or other unforeseen difficulties, or that shipping may be delayed or canceled in the event that unexpected technical difficulties arise during product finalization.